Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neumología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 4
ClinicalTrials.gov
Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer
INTERVENTIONAL
Inicio: 1 de ago de 2006
ID: NCT00451906
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
INTERVENTIONAL
Inicio: 24 de mar de 2022
ID: NCT05226598
Reclutando
Fase 2
ClinicalTrials.gov
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
INTERVENTIONAL
Inicio: 20 de jun de 2023
ID: NCT05789082
Completado
Fase 3
ClinicalTrials.gov
A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease
INTERVENTIONAL
Inicio: 25 de ene de 2011
ID: NCT01313676
Completado
Fase 3
ClinicalTrials.gov
A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants With Severe Asthma on High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Long-term Oral Corticosteroid Therapy (WAYFINDER)
INTERVENTIONAL
Inicio: 17 de may de 2022
ID: NCT05274815
Completado
ClinicalTrials.gov
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
INTERVENTIONAL
Inicio: 1 de jul de 2007
ID: NCT00428220
Activo, no recluta
Fase 1
ClinicalTrials.gov
A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis
INTERVENTIONAL
Inicio: 11 de nov de 2020
ID: NCT04454658
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
INTERVENTIONAL
Inicio: 1 de abr de 2012
ID: NCT01519804
Completado
ClinicalTrials.gov
An Observational, Multinational, Cross Sectional Primary Data Collection Study to Describe Symptoms Around 24-hs and Their Relationship With Adherence to Respiratory Treatment, Direct Costs and Patient Reported Outcomes (PRO) in Stable COPD Patients in Latin America.
OBSERVATIONAL
Inicio: 10 de jun de 2016
ID: NCT02789540
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults With Interstitial Lung Disease (ILD) Associated With Connective Tissue Disease (CTD)
INTERVENTIONAL
Inicio: 11 de sept de 2024
ID: NCT06572384
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)
INTERVENTIONAL
Inicio: 25 de sept de 2013
ID: NCT01933932
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)
INTERVENTIONAL
Inicio: 24 de may de 2024
ID: NCT06419374
Reclutando
Fase 2
ClinicalTrials.gov
A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)
INTERVENTIONAL
Inicio: 27 de jun de 2025
ID: NCT07082738
Completado
Fase 3
ClinicalTrials.gov
Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) for the Treatment of Patients With Severe Community-Acquired Pneumonia
INTERVENTIONAL
Inicio: 1 de may de 2004
ID: NCT00084071
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib
INTERVENTIONAL
Inicio: 16 de feb de 2024
ID: NCT06120140
Desconocido
Fase 3
ClinicalTrials.gov
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
INTERVENTIONAL
Inicio: 15 de ene de 2019
ID: NCT03662126
Por invitación
ClinicalTrials.gov
Utility of Pulmonary, Diaphragmatic and Cardiac Ultrasound Assessment During Weaning from Mechanical Ventilation in the Critically Ill Patient: a Prospective Observational
OBSERVATIONAL
Inicio: 10 de jun de 2024
ID: NCT06609798
Completado
Fase 3
ClinicalTrials.gov
MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial
INTERVENTIONAL
Inicio: 28 de sept de 2012
ID: NCT01691859
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
INTERVENTIONAL
Inicio: 24 de abr de 2018
ID: NCT03425643
Completado
Fase 2
ClinicalTrials.gov
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
INTERVENTIONAL
Inicio: 4 de nov de 2010
ID: NCT01218126
Anterior
1
...
30
31
32
...
434
Siguiente
Filtros